Pitavastatin reduces noncalcified plaque in people with HIV at low-to-moderate CVD risk
In people living with HIV (PWH) who are at low-to-moderate risk of cardiovascular disease (CVD), use of pitavastatin for 2 years leads to a reduction in noncalcified plaque volume and progression, which potentially contributes to a decrease in major adverse cardiovascular events (MACE), according to the results of the mechanistic substudy of the REPRIEVE trial.
